Woman smiling and holding a mobile phone and purse

VONJO HAS HELPED OTHER PEOPLE; IT MIGHT HELP YOU TOO

Not an actual patient.

How VONJO has helped people like you in the clinical study

In a 6-month clinical study, 107 people received 200 mg of VONJO twice a day, and 100 people received best available therapy (BAT), which included ruxolitinib, hydroxyurea, and monitoring without treatment. In this study, spleen volume reduction (the amount by which the spleen gets smaller) was measured. The main goal of the study was to see how many people with certain types of myelofibrosis (MF) and low platelet counts (less than 50,000 platelets per microliter) had their spleen shrink by 35% or more. This goal was measured in 31 people treated with VONJO compared to 32 people treated with BAT.1

10X
MORE

people had their spleen get at least 35% smaller with VONJO (29%) compared with people on best available therapy (3%)

The same study also looked at how many people had their spleen shrink by any amount.

More than 8 out of 10 people (83%) with MF had their spleen get smaller on VONJO

Image
Infographic representing 83% of myelofibrosis patients' spleen got smaller on VONJO compared to 56% receiving best therapy

compared with about 6 out of 10 people (56%) receiving best available therapy

With VONJO, the most common side effects that occurred in more than 2 out of 10 people (20%) in the study were:

  • Diarrhea
  • Nausea
  • Low platelet counts (thrombocytopenia) or low red blood cell counts (anemia)
  • Swelling of ankles, legs, and feet

These are not all the side effects with VONJO. Please read the Important Safety Information below.

Pacritinib (VONJO) is recommended by trusted cancer experts

The National Comprehensive Cancer Network (NCCN®) is a group of experts that creates guidelines to help doctors know what treatments are recommended for different kinds of cancer. They recommend pacritinib (VONJO) as a preferred treatment option for certain people with MF and platelet counts less than 50,000 per microliter.*

EXPLORE NCCN

* Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.1.2024. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed April 17, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

SIGN UP TO GET ACCESS TO SUPPORT, EDUCATIONAL RESOURCES, AND TOOLS TO HELP MANAGE MF.

Stay Connected

FIND OUT HOW TAKING VONJO COULD FIT INTO YOUR DAILY LIFE.